Bristol-Myers Will Cut Top Celgene Drug To Close $74B Deal
Bristol-Myers Squibb Co. said Monday it will spin off one of Celgene Corp.'s most lucrative drugs to hustle the pharmaceutical companies' $74 billion tie-up to the finish line, though the drugmaker...To view the full article, register now.
Already a subscriber? Click here to view full article